Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2002

View Archived Issues

Human Genome Sciences compounds advance into the clinic in second quarter

Apomine enters proof-of-principle trial in osteoporosis

Enrollment complete in tecadenoson phase III trial

Third-generation beta1/alpha-adrenoceptor blocker with hypotensive and bradycardic effects

Bifunctional fusion protein targeting breast cancer cells active in murine model

Safety and efficacy demonstrated for phVEGF2 in dose-escalating phase I/II trial

Liposomal TOP-53 may be associated with improved tolerance

Manufacturing approval obtained for Onoact

AstraZeneca presents new ERbeta ligands for AD and other disorders

Sepracor scientists identify new opioid and other GPCR ligands

Antidiabetic glucokinase activators identified at Roche

ZymoGenetics signs IL-13 receptor license agreement with Wyeth

Novel PPARalpha receptor agonists in the GSK pipeline

Roche scientists describe novel COX-2 inhibitors and their use

Major European launch for Otsuka antithrombotic agent

Carboxylic acid-based PPAR agonists in development at Kyorin

HDAC-inhibitory hydroxamates recently described in Roche patent

Genset licenses rights for Chlamydia genomic sequences to Ricerca

DNA minor groove-binding antitumor agent with potential in refractory tumors

Mitsubishi Chemical invests in IC-Vec for nonviral cancer gene therapy

GlaxoSmithKline to collaborate with elbion on PDE4 inhibitor development

Vernalis and Roche update obesity collaboration progress

Xyotax enters phase III evaluation in ovarian cancer

Roche licenses Alzheimer's compounds from Memory

Exhale licenses hyaluronic acid for prevention of group A streptococcal pharyngitis

Arixtra launched in Germany for preventing VTEs

Potential new treatment for cystic fibrosis designated an orphan drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...